June 26, 2015
A novel mediator of neuroinflammation and neuronal death resulting from stroke or inflammatory neurological disorders including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). They have also identified a potent inhibitor of these processes for use in prevention of neurological damage and neuroinflammation in stroke and neurological disorders.
Stroke is one of the leading causes of death in the United States, accounting for 1 of every 18 deaths and, when consider separately from other cardiovascular diseases, ranks no. 4 among all causes of death. Despite the prevalence of stroke, currently, the only FDA-approved drug for the treatment of stroke is the thrombolytic agent recombinant tissue plasminogen activator (rtPA) which holds several drawbacks including that it is severely limited by the need to use the drug within 4.5 hours after stroke to be effective and has an associated risk of symptomatic intracerebral hemorrhage. Thus, there is a need to find effective therapeutic agents to treat this and other neurological diseases. Recent research into inhibitors of MMPs have shown promise, given that MMPs are believed to promote neuronal death and neuroinflammation in stroke and neurodegenerative diseases via several mechanisms, including hemorrhagic transformation, infiltration and activation of inflammatory cells, direct neuronal toxicity, and anoikis via loss of neuronal contact with the extracellular matrix.
Researchers at the University of New Mexico through investigation of MMP inhibitors have found a novel mediator of neuroinflammation and neuronal death resulting from stroke or inflammatory neurological disorders including Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS). They have also identified a potent inhibitor of these processes for use in prevention of neurological damage and neuroinflammation in stroke and neurological disorders.
As the technology-transfer and economic-development organization for the University of New Mexico, STC.UNM protects and commercializes technologies developed at the University of New Mexico (UNM) by filing patents and copyrights and transferring the technologies to the marketplace. We connect the business communication (companies, entrepreneurs and investors) to these UNM technologies for licensing opportunities and the creation of startup companies. Visit www.stc.unm.edu.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
amyotrophic lateral sclerosis
symptomatic intracerebral hemorrhage
technology description researchers
direct neuronal toxicity
neuronal death resulting
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium